newsfilter
← Latest News
GlobeNewswire·

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled